ID

19065

Descripción

A Study of Pertuzumab in Participants With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02480010

Link

https://clinicaltrials.gov/show/NCT02480010

Palabras clave

Versiones (1)
  1. 2/12/16 2/12/16 -
Subido en

2 de diciembre de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostate Cancer DRKS00010313 NCT02480010

Inglés

Eligibility Prostate Cancer NCT02480010

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
adults greater than (>) 18 years of age
Descripción

Adult | Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
histologically documented adenocarcinoma of the prostate resistant to hormone therapy, progressed at 4 to 6 weeks following anti-androgen withdrawal
Descripción

Adenocarcinoma of prostate Hormone Therapy Resistant | Androgen Antagonists Withdrawal | Disease Progression

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007112
UMLS CUI [1,2]
C0279025
UMLS CUI [1,3]
C0332325
UMLS CUI [2,1]
C0002842
UMLS CUI [2,2]
C2349954
UMLS CUI [3]
C0242656
prostate-specific antigen (psa) values at least 20 ng/ml among those with asymptomatic or mildly symptomatic disease
Descripción

Prostate specific antigen measurement Asymptomatic Disease | Prostate specific antigen measurement Disease Symptomatic Mild

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0201544
UMLS CUI [1,2]
C2936329
UMLS CUI [2,1]
C0201544
UMLS CUI [2,2]
C0012634
UMLS CUI [2,3]
C0231220
UMLS CUI [2,4]
C2945599
karnofsky performance status (kps) at least 80 percent (%)
Descripción

Karnofsky Performance Status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0206065
castrate testosterone less than (<) 50 ng/dl
Descripción

Castrated male Testosterone measurement

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1319065
UMLS CUI [1,2]
C0523912
life expectancy at least 12 weeks
Descripción

Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
left ventricular ejection fraction (lvef) at least 50%
Descripción

Left ventricular ejection fraction

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0428772
adequate hematologic, hepatic, and renal function
Descripción

Hematologic function | Liver function | Renal function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior chemotherapy, radionucleotide therapy, or immunotherapy for prostate cancer
Descripción

Chemotherapy Prostate carcinoma | Immunotherapy Prostate carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0600139
UMLS CUI [2,1]
C0021083
UMLS CUI [2,2]
C0600139
systemic corticosteroids within 1 month prior to screening
Descripción

Adrenal Cortex Hormones Systemic

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C0205373
bisphosphonates within 6 months, narcotic analgesics within 2 weeks, or any investigational agent with 28 days of study drug
Descripción

Diphosphonates | Narcotic Analgesics | Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0012544
UMLS CUI [2]
C0027409
UMLS CUI [3]
C0013230
prior cumulative doxorubicin dose of > 360 mg/m^2 or equivalent
Descripción

Doxorubicin Cumulative Dose

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013089
UMLS CUI [1,2]
C2986497
central nervous system (cns) or pulmonary metastases
Descripción

CNS metastases | Secondary malignant neoplasm of lung

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2]
C0153676
other malignancies, except adequately treated basal or squamous cell skin cancer
Descripción

Malignant Neoplasms | Basal cell carcinoma Treated | Squamous cell carcinoma of skin Treated

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C0007117
UMLS CUI [2,2]
C1522326
UMLS CUI [3,1]
C0553723
UMLS CUI [3,2]
C1522326
significant cardiovascular disease
Descripción

Cardiovascular Disease Significant

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C0750502
active/uncontrolled concurrent illness or infection
Descripción

Comorbidity Uncontrolled | Communicable Disease Uncontrolled

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C0205318
major surgery or traumatic injury within 4 weeks of study drug
Descripción

major surgery | Traumatic injury

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2]
C3263723
Volver a la parte superior de la página

Similar models

Eligibility Prostate Cancer NCT02480010

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adults greater than (>) 18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Adenocarcinoma of prostate Hormone Therapy Resistant | Androgen Antagonists Withdrawal | Disease Progression
Item
histologically documented adenocarcinoma of the prostate resistant to hormone therapy, progressed at 4 to 6 weeks following anti-androgen withdrawal
boolean
C0007112 (UMLS CUI [1,1])
C0279025 (UMLS CUI [1,2])
C0332325 (UMLS CUI [1,3])
C0002842 (UMLS CUI [2,1])
C2349954 (UMLS CUI [2,2])
C0242656 (UMLS CUI [3])
Prostate specific antigen measurement Asymptomatic Disease | Prostate specific antigen measurement Disease Symptomatic Mild
Item
prostate-specific antigen (psa) values at least 20 ng/ml among those with asymptomatic or mildly symptomatic disease
boolean
C0201544 (UMLS CUI [1,1])
C2936329 (UMLS CUI [1,2])
C0201544 (UMLS CUI [2,1])
C0012634 (UMLS CUI [2,2])
C0231220 (UMLS CUI [2,3])
C2945599 (UMLS CUI [2,4])
Karnofsky Performance Status
Item
karnofsky performance status (kps) at least 80 percent (%)
boolean
C0206065 (UMLS CUI [1])
Castrated male Testosterone measurement
Item
castrate testosterone less than (<) 50 ng/dl
boolean
C1319065 (UMLS CUI [1,1])
C0523912 (UMLS CUI [1,2])
Life Expectancy
Item
life expectancy at least 12 weeks
boolean
C0023671 (UMLS CUI [1])
Left ventricular ejection fraction
Item
left ventricular ejection fraction (lvef) at least 50%
boolean
C0428772 (UMLS CUI [1])
Hematologic function | Liver function | Renal function
Item
adequate hematologic, hepatic, and renal function
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Chemotherapy Prostate carcinoma | Immunotherapy Prostate carcinoma
Item
prior chemotherapy, radionucleotide therapy, or immunotherapy for prostate cancer
boolean
C0392920 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0021083 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])
Adrenal Cortex Hormones Systemic
Item
systemic corticosteroids within 1 month prior to screening
boolean
C0001617 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
Diphosphonates | Narcotic Analgesics | Investigational New Drugs
Item
bisphosphonates within 6 months, narcotic analgesics within 2 weeks, or any investigational agent with 28 days of study drug
boolean
C0012544 (UMLS CUI [1])
C0027409 (UMLS CUI [2])
C0013230 (UMLS CUI [3])
Doxorubicin Cumulative Dose
Item
prior cumulative doxorubicin dose of > 360 mg/m^2 or equivalent
boolean
C0013089 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
CNS metastases | Secondary malignant neoplasm of lung
Item
central nervous system (cns) or pulmonary metastases
boolean
C0686377 (UMLS CUI [1])
C0153676 (UMLS CUI [2])
Malignant Neoplasms | Basal cell carcinoma Treated | Squamous cell carcinoma of skin Treated
Item
other malignancies, except adequately treated basal or squamous cell skin cancer
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2,1])
C1522326 (UMLS CUI [2,2])
C0553723 (UMLS CUI [3,1])
C1522326 (UMLS CUI [3,2])
Cardiovascular Disease Significant
Item
significant cardiovascular disease
boolean
C0007222 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
Comorbidity Uncontrolled | Communicable Disease Uncontrolled
Item
active/uncontrolled concurrent illness or infection
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
major surgery | Traumatic injury
Item
major surgery or traumatic injury within 4 weeks of study drug
boolean
C0679637 (UMLS CUI [1])
C3263723 (UMLS CUI [2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial